[REVISION HISTORY]

PMOS Renaming – Heart, Fertility & Mental Health

Updated 1 time since CLSTR started tracking revisions of this situation.

What changed

2026-07-27 14:47 UTC → 2026-08-01 15:46 UTC · added ~~removed~~

Following the May 2026 consensus to rename polycystic ovary syndrome as polyendocrine metabolic ovarian syndrome (PMOS) – later expanded to PC O AS – health agencies worldwide have begun embedding routine metabolic, cardiovascular and mental‑health checks into clinical pathways. Large U.S. insurance analyses and Lancet studies of over two million women consistently show a four‑fold increase in heart‑disease risk that persists after adjusting for hypertension, diabetes and obesity. A July 2026 systematic review identified effective anxiety‑depression interventions, while NICE drafts NHS reviews for up to four million women. A new Lancet‑published cohort of 2.4 million U.S. women (July 26) confirms the same quadruple cardiovascular risk and adds that PMOS disrupts obesity, alongside disrupted ovulation, ~~causing anovulation and~~ reduced fertility. Experts recommend earlier diagnosis, weight management, balanced diet, regular activity, and, when needed, anti‑obesity medication or bariatric surgery to improve insulin sensitivity, hormone balance fertility and ~~pregnancy prospects. The emerging evidence reinforces the need for integrated~~ heightened anxiety‑depression rates. Integrated screening that includes cardiovascular, metabolic, reproductive and mental‑health assessments is now recommended for all women with PMOS. A cross‑sectional study published in August 2026 examined 147 premenopausal women with Type 1 diabetes, including 30 diagnosed with PMOS. While overall lipoprotein and inflammatory glycoprotein profiles did not worsen after adjusting for age and diabetes duration, distinct lipid patterns emerged when PMOS co‑occurred with diabetes, and inflammatory markers were elevated in the combined group. A separate University of Pennsylvania analysis reaffirmed that women with PMOS are four times more likely to develop cardiovascular disease, a risk that remains after accounting for hypertension, diabetes and other factors, underscoring chronic under‑diagnosis. These findings extend earlier evidence to the diabetic sub‑population, highlighting the need for prospective research on PMOS‑related cardiometabolic risk and reinforcing calls for targeted cardiovascular monitoring, lifestyle interventions and, where appropriate, anti‑obesity or bariatric therapies to improve long‑term health outcomes.

Versions

Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.